Insider · CIK 0001830363
John Renger
Files at CERE (Cerevel Therapeutics Holdings, Inc.). First filing Feb 8, 2024, latest Feb 8, 2024.
In brief
John Renger files SEC Form 4 as officer at CERE (Cerevel Therapeutics Holdings, Inc.). Since Feb 8, 2024, John Renger has reported 0 open-market buys worth $0 and 1 open-market sell worth $90k, the latest filed on Feb 8, 2024.
A track record needs three past buys with six months of prices behind them; John Renger has 0, so none is measured yet.
The newest scored trade: sold $90k of CERE on Feb 7, 2024, filed Feb 8, 2024, scored 27 (weak).
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 27Weak | Cerevel Therapeutics Holdings, Inc. | $90k 2,161 shares | -25% | - |
Transactions
Every row this insider has filed, 8 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Aug 1, 2024 | CERE Cerevel Therapeutics Holdings, Inc. | DDisposition to issuer Common Stock | -6,370 | - | - | 0 | Aug 5, 2024 |
| Aug 1, 2024 | CERE Cerevel Therapeutics Holdings, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -778,418 | - | - | 0 | Aug 5, 2024 |
| Aug 1, 2024 | CERE Cerevel Therapeutics Holdings, Inc. | DDisposition to issuer Restricted Stock Unitsderivative | -15,061 | $0.00 | $0 | 0 | Aug 5, 2024 |
| Aug 1, 2024 | CERE Cerevel Therapeutics Holdings, Inc. | DDisposition to issuer Restricted Stock Unitsderivative | -87,573 | $0.00 | $0 | 0 | Aug 5, 2024 |
| Feb 6, 2024 | CERE Cerevel Therapeutics Holdings, Inc. | MOption exercise Common Stock | +5,020 | - | - | 8,531 | Feb 8, 2024 |
| Feb 7, 2024 | CERE Cerevel Therapeutics Holdings, Inc. | SOpen-market sale Common Stock | -2,161 | $41.54 | $90k | 6,370 | Feb 8, 2024 |
| Feb 6, 2024 | CERE Cerevel Therapeutics Holdings, Inc. | MOption exercise Restricted Stock Unitsderivative | -5,020 | $0.00 | $0 | 15,061 | Feb 8, 2024 |
| Jan 19, 2024 | CERE Cerevel Therapeutics Holdings, Inc. | AGrant or award Restricted Stock Unitsderivative | +87,573 | $0.00 | $0 | 87,573 | Jan 23, 2024 |
Questions about John Renger
Answered from the filings on this page, as of the latest one.
Is John Renger buying or selling?
Not in the last 12 months. John Renger's latest open-market trade on SEC Form 4 was sold $90k of CERE on Feb 7, 2024.
How did John Renger's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and John Renger has 0.
Where does John Renger file Form 4?
John Renger has filed Form 4 at CERE (Cerevel Therapeutics Holdings, Inc.) as Chief Scientific Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.